Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. Its products include Nidlegy, Fibromun, Darleukin, Dodekin, and Dekavil. The company was founded by Dario Neri, Duccio Neri, and Giovanni Neri in 1996 and is headquartered in Siena, Italy.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company